As previously reported, Baird initiated coverage of Fortrea Holdings with a Neutral rating and $43 price target. The firm, which says it is “still early chapters in Fortrea’s remaking,” admits to being “torn between alternative bullish and not-so-bullish perspectives.” Fortrea lags peers notably on almost every metric, while the current valuation already credits 2025-plus potential, says the firm, though it adds that there are “idiosyncratic and technical merits that investors shouldn’t sleep on, given the right opportunity.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FTRE:
- Fortrea Holdings price target raised to $33 from $29 at BofA
- Fortrea Holdings Announces Sale of Key Divisions
- Fortrea Holdings sees 2024 revenue $3.14B-$3.205B, consensus $3.2B
- Fortrea to divest Endpoint Clinical, Fortrea Patient Access for $345M
- Fortrea Holdings reports Q4 adjusted EPS 19c, consensus 24c